1 terminated. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Avenge Bio, Inc: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary AVB-001 (Dose Escalation Phase), AVB-001 (Dose Expansion Phase) - Neoplasm, Ovarian, Fallopian Tube Cancer | Phase 1 / Phase 2 | Terminated | Avenge Bio, Inc | 14 | 2022-12-09 | 2024-04-24 |
Fallopian Tube Neoplasms (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1)
United States (1)